Why can supply-chain finance (reverse factoring) be reclassified from trade payables to debt, and why do investors and rating agencies care?
An advanced Corporate Treasury question — expect it in final rounds and case-heavy interviews (IB, PE, Big-4 Transaction Services).
THE SHORT ANSWER
In reverse factoring a bank pays the supplier early and the company repays the bank later. Accounting-wise it can look like ordinary payables, but if the arrangement changes the character of the liability — extended terms well beyond normal, the bank effectively providing financing, security or guarantees — it economically resembles bank borrowing. Rating agencies and investors care because companies have used SCF to stretch payables and flatter both leverage (debt looks lower) and operating cash flow (the financing sits in working capital, not financing activities). High-profile failures (e.g., Carillion, Greensill-linked situations) showed it can hide a liquidity dependence that collapses if the SCF program is withdrawn. Disclosure rules have tightened, and analysts now adjust by reclassifying material SCF as debt and recharacterizing the cash-flow geography.
WHAT INTERVIEWERS LISTEN FOR
- ✓SCF can economically be financing, not pure payables
- ✓Used to flatter leverage and operating cash flow
- ✓Withdrawal risk = hidden liquidity dependence
- ✓Analysts reclassify material SCF as debt
COMMON MISTAKES
- ✗Treating all SCF as benign payables
- ✗Ignoring cash-flow classification impact
- ✗No awareness of disclosure/withdrawal risk
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you prepare for a rating agency meeting?
- A company has a €500M bond maturing in 2 years and a €300M RCF undrawn. The CFO wants to refinance now to lock in low rates. You notice the RCF has a material adverse change (MAC) clause. How does this affect your refinancing strategy?
- A company has a €200M RCF with a net leverage covenant of 3.5x. After a large acquisition, net debt/EBITDA is 3.8x. You have a cure right to inject equity. The CFO asks: should we cure now or wait? What factors drive your decision?
- Why do rating agencies and investors expect a commercial paper program to be backed by committed bank lines, and how much backup is appropriate?
- Walk me through the covenant compliance certificate process and why the credit agreement's EBITDA definition matters so much.
- What is a make-whole call provision, and how does it affect the economics of redeeming a bond early?